These eight projects took top marks in the three office subcategories for this year's Best Real Estate Deals awards program.

Shares of Incyte Corp. INCY rose 1.39% to $62.78 Monday, on what proved to be an all-around positive trading session for the ...

The stock's fall snapped a four-day winning streak.

Morgan Stanley lowered the firm’s price target on Incyte (INCY) to $65 from $69 and keeps an Equal Weight rating on the shares. Based on the ...

Incyte (INCY – Research Report) received a Hold rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...

Investment analysts at William Blair increased their Q2 2025 EPS estimates for shares of Incyte in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps now expects that the ...

Incyte had a return on equity of 0.05% and a net margin of 0.77%. On average, equities research analysts predict that Incyte Co. will post 4.86 EPS for the current fiscal year. Incyte Profile ...

Incyte’s The Unseen Journey illustrates the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials ...

Analysts are intrested in these 5 stocks: ( ($MNDY) ), ( ($INCY) ), ( ($LCID) ), ( ($BE) ) and ( ($EQT) ). Here is a ...

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.